To determine the therapeutic capacity of VEN-02XX in neurodegenerative diseases, and the contribution of inflammasome signaling to the observed AD pathology downstream of CASM-deficiency, the 5XFAD/Rubicon knockout mice were treated following symptomatic and neuropathological establishment. The gene discussed is LSM1; the disease is Alzheimer disease.